Abstract: 61 words 10
During a 9-month period, 217 patients were newly diagnosed as MRSA carriers with a 1 commercial rapid PCR-based test (GeneXpert). However, no MRSA was recovered by 2 culturing the second swab in 61 of these patients. Further analyses showed that 28 (12.9%) 3 patients harbored S. aureus isolates with a SCC element lacking the mecA gene and were thus 4 wrongly considered as MRSA carriers. 5 6 7 Rapid and accurate detection of methicillin resistant Staphylococcus aureus (MRSA) is a key 1 element for early therapy and implementation of control measures to prevent onward 2 transmission from carriers (5) (6) (7) 15, 16) . Recently developed PCR-based methods have the 3 potential to confirm or refute MRSA carriage in individual patients within 2 hours. PCR 4 detection of MRSA from clinical specimens requires primers specific to the different 5 staphylococcal cassette chromosome mec (SCCmec) elements at their 3' extremity sequence 6 and a primer specific to the S. aureus chromosomal sequence located at the 3' of the SCCmec 7 integration site (9). However, the rapid PCR test will generate a false positive result in the 8 presence of SCC elements lacking the mecA gene (10,11). For example, it was reported that 9 4.6% of 569 MSSA were PCR positive with a PCR targeting the SCCmec element (8). Such 10 false positive results may lead to several unjustified actions such as i) the empirical use of 11 glycopeptide compounds instead of beta-lactam antibiotics, ii) decolonization treatments, and 12 iii) isolation of patients and other constraining infection control measures. The purpose of this 13 study was to evaluate the proportion of patients wrongly identified as MRSA carriers with a 14 rapid commercial PCR test. 15
The University Hospital of Lausanne is a 900 beds tertiary care hospital where active 16 surveillance cultures are part of its MRSA control program. The rapid PCR-based test 17 (GeneXpert system, Cepheid, Sunnyvale, CA) was introduced in June 2009 for screening 18 MRSA in nose, throat, and groin swabs in addition to screening performed by culture. 19
Samples were obtained using a double-swab transystem (Copan, Brescia, Italy) . In order to 20 isolate the MRSA strain for further molecular typing, all second swabs were cultured when > 21 1 sample was found positive in a screening set (nose, throat, and groin). Culture included an 22 overnight incubation in an enrichment broth (m-Staphylococcus broth, Difco, Basel, 23 Switzerland) followed by inoculation onto a chromogenic agar medium (MRSA-select; Bio-24 Rad, Marnes-la-Coquette, France). During the study period, a 1 mL aliquot of all enrichment 1 broths was stored frozen for further analyses. whereas 61 (28 %) had negative cultures. Enrichment broths were available for 58 of these 61 6 patients with negative cultures. They were thawed and plated onto chromogenic S. aureus 7 agar plates (SA-ID; bioMérieux, Marcy l'Etoile, France). For 28 of these patients, we 8 retrieved isolates of S. aureus that were positive by the rapid PCR test. Antibiotic 9 susceptibility testing was performed on these isolates with the Kirby-Bauer method as already 10 described (2). All showed a methicillin-susceptible phenotype (oxacillin-S and cefoxitine-S). 11
A PCR that amplified the mecA gene was also performed as previously described (6) and 12 confirmed the absence of this gene. Characteristics of these isolates are given in Table. Thus,  13 28 of the 217 (12.9%) newly identified MRSA carriers by rapid commercial PCR test 14 harbored a S. aureus strain which did not contain the mecA gene. 15
Most patients harboring a MSSA strain positive with the rapid MRSA test were subsequently 16 screened several times for MRSA by culture, and no MRSA was recovered. The 17 consequences for these patients were unnecessary decolonization procedures, which are time 18 and labor consuming, and isolation with contact precautions which has been associated with 19 lower patient care in several studies. In one case, the patient was cohorted with other MRSA 20 positive patients, and subsequently became colonized with the roommates' strain. The presence of a SCC element that doesn't contain the mecA gene might be due to the loss of 5 this gene. In this case, we would expect that most of the false positive isolates be genetically 6 related to predominant MRSA clones in the area. To investigate this hypothesis, all MSSA 7
isolates of the present study were genotyped by the Double Locus Sequence Typing 8 (sequencing of c.a. 500 bp of clfB and spa genes (13)) and MLST methods (4) as previously 9 described. A great diversity of genotypes was observed suggesting the non clonal 10 dissemination of one strain (Table) . An excision of the mecA gene could be suspected in 4 11 cases since these strains showed a genotype related to local epidemic MRSA (Lyon clone: 12 DLST 3-3, ST 8-IV; and a variant of the New York/ Japan clone: DLST 2-2, ST 105-II) (1). 13
Such loss of the mecA gene was previously described during the emergence and spread of the 14 Lyon clone (ST 8-SCCmec IV) in French hospitals (2,3). Partial excision of SCCmec was 15 suggested since SCCmec associated elements were still present in these trains and their 16 genotype were related to the epidemic MRSA. Nevertheless, the majority of genotypes 17 observed in our MSSA isolates were not related to local predominant MRSA clones ( Table) , 18
suggesting that these MSSA with partial SCCmec element did not emerged from local MRSA. 19
Further studies should be done to investigate if these isolates harbored non-mec-containing 20 SCC elements, as was described in MSSA and other staphylococcal species (12, 14) . 21
In conclusion, this work identified a high proportion (12.9%) of patients wrongly considered 22 as MRSA carriers using a rapid commercial test for MRSA screening. This was due to the 23 presence of S. aureus with SCC element lacking the mecA gene. These false positive results 24 lead to inappropriate patient care (unnecessary decolonization treatment, additional 25 precautions measures and possibly unjustified use of glycopeptides). In the future, more 1 insight is needed on the performance of these molecular tests, and ideally new generation tests 2 should circumvent the current limitations. 
